Using PD-1/PD-L1 and/or CTLA-4 inhibitors results in much longer overall survival rates, especially among melanoma, lung and bladder cancer patients (Hodi et al. 2010; Schachter et al. 2017; Naik et al. 2021). The gene discussed is CD274; the disease is urinary bladder cancer.